Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 319-325

  Bozkaya, Hakan ^a   Yurdaydin, Cihan ^a   Idilman, Ramazan ^a   Tüzün, Ali ^a   Cinar, Kubilay ^a   Erkan, Özlem ^a   Bozdayi, A Mithat ^a   Erden, Esra ^a   Uzun, Yusuf ^b   Cetinkaya, Hülya ^a   Uzunalimoglu, Özden ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b BLACK SEA TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA; HEPATITIS B(E) ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SEX RATIO; STATISTICAL ANALYSIS; VIREMIA; VIRUS MUTANT; WILD TYPE; BLOOD; GENETICS; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; VIREMIA;

EID: 22844448307     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lok ASF, Heathcote EJ & Hoofnagle JH. Management of hepatitis B 2000, summary of a workshop. Gastroenterology 2001; 120:1828-1853.
2. Chu CJ & Lok ASF. Clinical utility in quantifying serum HBV DNA levels using PCR. Journal of Hepatology 2002; 36:549-551.
3. Hadziyannis SJ & Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
4. Manesis EK, Paptheodoridis GV & Hadziyannis SJ. Serum HBV DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002; 122:2092-2093.
5. Brunetto MR, Olivieri F, Coco B, Leandro G, Colombatto P, Gorin JM & Bonino F. Outcome of anti-Hbe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. Journal of Hepatology 2002; 36:263-270.
6. Chu CJ, Hussain M & Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2003; 36:1408-1415.
7. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC & McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 1996; 93:4398-4402.
8. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M & Brown NA. Lamivudine as initial treatment for chronic hepatitis B. New England Journal of Medicine 1999; 341:1256-1263.
9. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL & Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine 1998; 339:61-68.
10. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
11. Santantonio T, Mazzola M, Lacovazzi T, Miglietta A, Guastadisegni A & Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. Journal of Hepatology 2000; 32:300-306.
12. Hadziyannis SJ, Papatheodoridis GV, Edimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000; 32:847-851.
13. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226.
14. Scotto G, Fazio V, Campanozzi F & Fazio V. Efficacy of treatment with lamivudine in patients with chronic active e-minus variant hepatitis B virus infection: a non-randomized, open label study. Current Therapeutic Research 2000; 61:321-330.
15. Rizetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. Journal of Medical Virology 2002; 66:435-451.
16. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L & Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29:889-896.
17. Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Toruner M, Erkan O, Heper A, Erden E, Bozdayi AM & Uzunalimoglu O. Treatment of HBeAg (-) chronic hepatitis B with lamivudine vs lamivudine+interferon: a randomized controlled clinical trial. Journal of Viral Hepatitis 2005; in press.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW & Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA & Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999; 94:2467-2474.
20. Bozkaya H, Yurdaydin C, Bozdayi AM, Erkan O, Karayalcin S & Uzunalimoglu O. Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study. Clinical Infectious Diseases 2002; 35:960-965.
21. Marinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C & Marcellin P. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. Journal of Hepatology 2002; 36:543-546.
22. Lai CL & Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. Journal of Medical Virology 2000; 61:367-373.
23. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F & Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. Journal of Clinical Investigation 1998; 102:968-975.
24. Stuyver L, Van Geyt C, De Gent S, Van Reybroeck G, Zoulim F, Leroux-Roels G & Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. Journal of Clinical Microbiology 2000; 38:702-707.
25. Pas SD, de Man RA, Fries E, Osterhaus AD & Niesters HG. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization. Journal of Clinical Virology 2002; 25:63-71.
26. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T & Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. Journal of Hepatology 2002; 37:259-265.